XTX Topco Ltd Buys 17,683 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

XTX Topco Ltd increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 259.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,499 shares of the company's stock after purchasing an additional 17,683 shares during the period. XTX Topco Ltd's holdings in Harmony Biosciences were worth $813,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. GSA Capital Partners LLP bought a new stake in Harmony Biosciences in the 1st quarter worth approximately $688,000. Skandinaviska Enskilda Banken AB publ bought a new stake in Harmony Biosciences in the 1st quarter worth approximately $544,000. Hedeker Wealth LLC lifted its position in Harmony Biosciences by 2.0% in the 1st quarter. Hedeker Wealth LLC now owns 77,734 shares of the company's stock worth $2,580,000 after buying an additional 1,531 shares during the last quarter. Cetera Investment Advisers lifted its position in Harmony Biosciences by 10.9% in the 1st quarter. Cetera Investment Advisers now owns 7,656 shares of the company's stock worth $254,000 after buying an additional 754 shares during the last quarter. Finally, Legato Capital Management LLC lifted its position in Harmony Biosciences by 19.4% in the 1st quarter. Legato Capital Management LLC now owns 31,911 shares of the company's stock worth $1,059,000 after buying an additional 5,191 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Cantor Fitzgerald upgraded Harmony Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. Needham & Company LLC restated a "buy" rating and set a $49.00 price target on shares of Harmony Biosciences in a research report on Tuesday, May 6th. UBS Group reduced their price target on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. Truist Financial initiated coverage on Harmony Biosciences in a research report on Monday, July 21st. They set a "buy" rating and a $48.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $51.00.

Harmony Biosciences Trading Down 2.2%

HRMY opened at $34.40 on Monday. The business has a 50 day simple moving average of $34.09 and a two-hundred day simple moving average of $33.93. Harmony Biosciences Holdings, Inc. has a one year low of $26.47 and a one year high of $41.61. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of 13.13, a PEG ratio of 0.47 and a beta of 0.84. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.67 and a quick ratio of 3.63.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.19. Harmony Biosciences had a return on equity of 24.32% and a net margin of 20.53%. The company had revenue of $184.73 million during the quarter, compared to analyst estimates of $184.26 million. During the same quarter last year, the firm posted $0.67 earnings per share. The firm's revenue was up 19.5% on a year-over-year basis. Analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.